News
GSK falls
Digest more
ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...
Zacks Investment Research on MSN10d
GSK's Specialty Medicines Unit on a Strong Footing: Here's WhyGSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...
The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for treatment in 133 countries.
GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...
No investor will be happy with their GSK shares as the FTSE 100 pharmaceutical giant has had a dismal decade. Will the next ...
GlobalData on MSN4d
ViiV’s HIV shot preferred, as activists spotlight funding crisis at IAS 2025Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.
Hyderabad-based drugmaker Aurobindo Pharma will produce and supply Cabotegravir, a long-acting injectable HIV treatment, ...
UK-based ViiV Healthcare, the HIV specialist company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced data from the Phase IIIb VOLITION study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback